JP7164885B2 - 虚血／再灌流障害 - Google Patents

虚血／再灌流障害 Download PDF

Info

Publication number
JP7164885B2
JP7164885B2 JP2019529143A JP2019529143A JP7164885B2 JP 7164885 B2 JP7164885 B2 JP 7164885B2 JP 2019529143 A JP2019529143 A JP 2019529143A JP 2019529143 A JP2019529143 A JP 2019529143A JP 7164885 B2 JP7164885 B2 JP 7164885B2
Authority
JP
Japan
Prior art keywords
bag3
pharmaceutical composition
ischemia
vector
reperfusion injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527736A (ja
JP2019527736A5 (https=
Inventor
アーサー エム． フェルドマン，
ジョセフ ワイ． チェン，
カメル ハリリ，
Original Assignee
テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション filed Critical テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション
Publication of JP2019527736A publication Critical patent/JP2019527736A/ja
Publication of JP2019527736A5 publication Critical patent/JP2019527736A5/ja
Application granted granted Critical
Publication of JP7164885B2 publication Critical patent/JP7164885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019529143A 2016-08-11 2017-08-10 虚血／再灌流障害 Active JP7164885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662373410P 2016-08-11 2016-08-11
US62/373,410 2016-08-11
PCT/US2017/046237 WO2018031738A2 (en) 2016-08-11 2017-08-10 Ischemia/reperfusion injury

Publications (3)

Publication Number Publication Date
JP2019527736A JP2019527736A (ja) 2019-10-03
JP2019527736A5 JP2019527736A5 (https=) 2020-09-17
JP7164885B2 true JP7164885B2 (ja) 2022-11-02

Family

ID=61162527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019529143A Active JP7164885B2 (ja) 2016-08-11 2017-08-10 虚血／再灌流障害

Country Status (10)

Country Link
US (2) US20190183971A1 (https=)
EP (1) EP3496726A4 (https=)
JP (1) JP7164885B2 (https=)
KR (2) KR20240130829A (https=)
CN (1) CN109937045A (https=)
AU (2) AU2017311405B2 (https=)
CA (1) CA3033633A1 (https=)
IL (2) IL264760B2 (https=)
MX (1) MX2019001729A (https=)
WO (1) WO2018031738A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438159B (zh) * 2019-07-03 2023-02-28 广州中医药大学(广州中医药研究院) 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法
CN113082048B (zh) * 2021-05-08 2022-06-10 中国人民解放军陆军军医大学第二附属医院 一种Se@BSA纳米药物的制备方法及其在急性肾损伤中的应用
CN113502260A (zh) * 2021-07-16 2021-10-15 新疆医科大学第一附属医院 一种小鼠乳鼠原代心肌细胞分离与培养方法及其应用
JP2025514489A (ja) * 2022-05-03 2025-05-02 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 脳におけるｂａｇ３およびタンパク質品質管理

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US20030175958A1 (en) * 2002-03-15 2003-09-18 Reed John C. Methods for using bag expression as a cell differentiation agent and marker
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
KR101436684B1 (ko) * 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Brain Research, 2010, Vol.1349, No.19, pp.1-10
Cell Physiol Biochem, 2016.7, Vol.39, pp.491-500
J. Cell Physiol., 2014, Vol.229, No.11, pp.1697-1702
JCI Insight, 2016.11, Vol.1, No.19, e90931
Med Sci Monit, 2016.01 Epub, Vol.22, pp.977-983
日本医科大学医学会雑誌, 2012, Vol.8, No.3, pp.216-221
日本薬理学雑誌, 1996, Vol.108, pp.195-202

Also Published As

Publication number Publication date
JP2019527736A (ja) 2019-10-03
IL264760B1 (en) 2023-03-01
AU2023237152B2 (en) 2026-01-22
EP3496726A4 (en) 2020-05-06
KR20240130829A (ko) 2024-08-29
KR20190042609A (ko) 2019-04-24
US20190183971A1 (en) 2019-06-20
CN109937045A (zh) 2019-06-25
IL300767A (en) 2023-04-01
CA3033633A1 (en) 2018-02-15
MX2019001729A (es) 2019-11-12
US20230390357A1 (en) 2023-12-07
AU2023237152A1 (en) 2023-10-19
IL264760B2 (en) 2023-07-01
IL264760A (https=) 2019-03-31
WO2018031738A2 (en) 2018-02-15
EP3496726A2 (en) 2019-06-19
IL300767B1 (en) 2026-03-01
AU2017311405B2 (en) 2023-07-13
AU2017311405A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2023237152B2 (en) Ischemia/Reperfusion injury
Joshi et al. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury
US20250001014A1 (en) Bag3 compositions and methods
US11021528B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
Ding et al. Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 1
JP2019527736A5 (https=)
US20260069622A1 (en) Compositions and methods for treating vascular malformation and related conditions
Zeng et al. LncRNA PART1 attenuates myocardial ischemia-reperfusion injury by regulating TFAP2C/DUSP5 axis via miR-302a-3p
Dong et al. Down-regulation of miR-192 protects against rat ischemia-reperfusion injury after myocardial infarction.
US6667173B2 (en) Nucleic acids encoding platelet derived growth factor-alpha receptors
US11560412B2 (en) Compositions comprising GRIM-19 therapeutics and methods of use
US12577292B2 (en) Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent
US12605398B2 (en) CRISPR-based compositions for treating vascular disorders
CA3200841A1 (en) Peptide inhibitors of human mitochondrial fission protein 1 and methods of use
US20090181911A1 (en) Role of gax in alzheimer neurovascular dysfunction
US9675590B2 (en) Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes
US20250250324A1 (en) Novel fusion protein for eliminating neurodegenerative disease-causing factor and use thereof
US9861615B2 (en) Methods and pharmaceutical compositions for the treatment of beta-thalassemias
WO2016083625A1 (en) Nucleic acid encoding triadin for the prevention and/or treatment of heart failure
HK40056903B (zh) 用於疾病治疗的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221014

R150 Certificate of patent or registration of utility model

Ref document number: 7164885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250